中文There is a quiet kind of confidence in a company that reports record order backlogs while its neighbours are whispering about downturns. Syntegon, the German packaging and processing giant, just delivered exactly that — and the numbers tell a story the whole packaging sector should read twice.
For the first half of 2026, Syntegon posted group sales of EUR 883 million, up 7% year-on-year. Adjusted EBITDA rose 16% to EUR 148 million, pushing the margin to 16.8% — up 130 basis points on the same period in 2025. Order intake reached EUR 964 million, a book-to-bill ratio of 1.09, and a record order backlog of EUR 1.3 billion. In plain English: they booked more than they shipped, and the pipeline has never been fuller.
Pharma is the engine, and it is roaring
CEO Torsten Türling did not hide where the strength came from: ‘Our Pharma business remains our strongest growth engine.’ Pharma sales jumped 14% in the first half, making it the top contributor to group growth. The drivers are structural, not cyclical — the expansion of biologics and injectable medicines, demand for more flexible and highly automated production, and tightening regulation that all favours serious, compliant suppliers. Aseptic Fill & Finish and isolator-equipped lines stayed hot, and Pharma Solid also grew double digits on capsule-filling demand.
Geography tells its own story. Europe remained a resilient core. Asia rose substantially, with market-share gains in biologics and a boost from local operations in China. And in the United States, pharma order intake climbed sharply on the back of a focused regional growth strategy. For a company that has spent years building lifecycle-partner relationships, the payoff is arriving in actual orders.
The food side is the honest footnote
No result is a straight line, and Syntegon’s candour here is refreshing. In food — particularly chocolate and bars, where the company is the global market leader — market dynamics stayed challenging. Customers felt cost pressure and went cautious on investment. Rather than pretend otherwise, Syntegon launched new efficiency- and flexibility-focused solutions, pointing to growing adoption of its SVX vertical packaging platform, and said it is taking measures to defend its margin.
That duality is the real lesson. Packaging machinery is not a single market; it is two moods at once. Pharma spends because regulators and patients demand it. Food trims because shoppers pinch pennies. A supplier balanced across both can post record numbers even when half its world is tightening.
‘Factory of the Future’ is not a slogan here
CFO Eros Carletti noted that adjusted EBITDA grew ‘more than twice as fast as sales’ — a sign of operating leverage, disciplined execution and a richer pharma mix. Syntegon frames the next wave as the ‘Factory of the Future’: next-generation solutions with enhanced automation, robotics and AI-enabled functionality, backed by lifecycle services that drive the lowest total cost of ownership across a customer’s footprint.
The company confirmed its full-year 2026 outlook of growth and margin expansion, citing a healthy order book and sustained pharma demand. For an industry watching input costs and labour shortages, that is about as steady a signal as you get.
The emotional takeaway? The firms that treat a downturn as a reason to invest in automation are the ones posting records while everyone else waits for the weather to change. Syntegon, this half, is Exhibit A.
Source: THE PACKMAN (NewsDesk), 8 September 2026.
